Abstract Background Immune checkpoint inhibitors (ICIs) have activity across many tumor
types, but activation of the immune system may also lead to significant, often steroid …

Background Adjuvant dabrafenib plus trametinib therapy improves relapse-free survival in
patients with resected stage III melanoma. We aimed to ascertain the proportion of patients …

Abstract Purpose of Review This report highlights several of the recent therapeutic
advancements in the treatment of BRAF-mutant tumors, discusses the most common …

Background Dabrafenib plus trametinib has demonstrated clinical benefit across multiple
BRAF-mutant tumours, leading to approval for resected stage III and metastatic melanoma …

Background: BRAF and MEK inhibitors are cornerstones of the redifferentiation strategy in
metastatic radioactive iodine (RAI)-resistant mutant thyroid cancers. We explored the …

Background Trametinib is a MEK1 (mitogen-activated extracellular signal-related kinase
kinase 1) inhibitor used in the treatment of BRAF (rapid accelerated fibrosarcoma B-type) …

Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual
variability in clinical outcomes. The aims of this study were to characterize the …

Pyrexia is a frequent adverse event of BRAF/MEK-inhibitor combination therapy in patients
with metastasized malignant melanoma (MM). The study's objective was to identify …

BRAF mutant metastatic melanoma was regularly treated in the past with a BRAF inhibitor
(BRAFi) alone or in combination with inhibitors of the mitogen-activated protein kinase …

Simple Summary In melanoma patients treated with dabrafenib and trametinib, dose
reductions and treatment discontinuations related to adverse events (AE) occur frequently …